SG11201908857QA - Methods for the treatment of inflammation and inflammatory conditions - Google Patents

Methods for the treatment of inflammation and inflammatory conditions

Info

Publication number
SG11201908857QA
SG11201908857QA SG11201908857QA SG11201908857QA SG 11201908857Q A SG11201908857Q A SG 11201908857QA SG 11201908857Q A SG11201908857Q A SG 11201908857QA SG 11201908857Q A SG11201908857Q A SG 11201908857QA
Authority
SG
Singapore
Prior art keywords
methods
international
lactobacillus
pct
treating
Prior art date
Application number
Other languages
English (en)
Inventor
Wayne Finlayson
Original Assignee
Servatus Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017901320A external-priority patent/AU2017901320A0/en
Application filed by Servatus Ltd filed Critical Servatus Ltd
Publication of SG11201908857QA publication Critical patent/SG11201908857QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201908857Q 2017-04-11 2018-04-11 Methods for the treatment of inflammation and inflammatory conditions SG11201908857QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2017901320A AU2017901320A0 (en) 2017-04-11 Methods for the treatment of inflammation and inflammatory conditions
AU2017902271A AU2017902271A0 (en) 2017-06-15 Methods for the treatment of inflammation and inflammatory conditions
PCT/AU2018/050326 WO2018187838A1 (en) 2017-04-11 2018-04-11 Methods for the treatment of inflammation and inflammatory conditions

Publications (1)

Publication Number Publication Date
SG11201908857QA true SG11201908857QA (en) 2019-10-30

Family

ID=63792160

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201908857Q SG11201908857QA (en) 2017-04-11 2018-04-11 Methods for the treatment of inflammation and inflammatory conditions

Country Status (8)

Country Link
US (1) US20200376047A1 (de)
EP (1) EP3609515A4 (de)
JP (1) JP7494110B2 (de)
CN (1) CN110753553A (de)
AU (1) AU2018251616A1 (de)
CA (1) CA3059453A1 (de)
SG (1) SG11201908857QA (de)
WO (1) WO2018187838A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109172613B (zh) 2018-08-14 2022-04-22 景岳生物科技(中国)有限公司 含乳杆菌死菌培养物的皮肤外用组合物及其于促进伤口愈合及降低疤痕产生的用途
CN114206362A (zh) * 2018-10-10 2022-03-18 赛瓦图斯有限公司 炎性状况和相关感染的治疗方法
GB201905386D0 (en) * 2019-04-16 2019-05-29 Probi Ab Probiotic compositions and uses thereof
EP3815700A1 (de) * 2019-10-30 2021-05-05 Biomillenia SAS Medizinische zusammensetzungen und deren verwendung in der behandlung von entzündlicher darmerkrankung
US20210267232A1 (en) * 2020-02-28 2021-09-02 Terragen Holdings Limited Microbial feed supplement composition and method
EP4125972A1 (de) * 2020-03-31 2023-02-08 Servatus Ltd Kombinationstherapie für entzündliche darmerkrankung
CN111733110B (zh) * 2020-07-17 2021-10-22 佛山市朗芯生物科技有限公司 副干酪乳杆菌及其在制备治疗溃疡性结肠炎药物中的应用
CN114470007A (zh) * 2020-11-13 2022-05-13 葡萄王生技股份有限公司 含乳酸菌发酵产物之创伤外用组合物及其用途
WO2022115907A1 (en) * 2020-12-01 2022-06-09 Servatus Ltd Methods for improving sleep quality
WO2022120421A1 (en) * 2020-12-09 2022-06-16 Servatus Ltd Combination therapy for inflammatory disorders of the joints
CN112522160B (zh) * 2020-12-24 2022-05-10 广东省科学院微生物研究所(广东省微生物分析检测中心) 一株具有抗病毒能力的发酵乳杆菌pv22及其应用
KR102268128B1 (ko) * 2021-02-09 2021-06-22 주식회사 락토메이슨 모유 유래 신규한 락토바실러스 루테리 lm1071 균주, 및 상기 균주 또는 이의 배양물을 포함하는 월경전 증후군 완화용 조성물
CN114456967B (zh) * 2021-10-14 2022-10-04 命之源(杭州)生物科技有限公司 一种酵母、乳酸菌联合菌、培育方法及其应用
WO2023097375A1 (en) * 2021-12-02 2023-06-08 Servatus Ltd Methods for the treatment of constipation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1593382A1 (de) * 2000-10-06 2005-11-09 Société des Produits Nestlé S.A. Verwendung von probiotische Milchsäure-produzierende Bakterien zur Beeinflüssung des Immunsystems der Haut
US20030175305A1 (en) * 2002-01-08 2003-09-18 Garner Bryan E. Compositions and methods for inhibiting pathogenic growth
US20040208863A1 (en) 2003-01-30 2004-10-21 James Versalovic Anti-inflammatory activity from lactic acid bacteria
AU2013201442B2 (en) * 2005-09-28 2014-10-30 Nordic Rebalance A/S Treatment of IBD and IBS using both probiotic bacteria and fermented cereal as treatment effectors
AU2007324791A1 (en) * 2006-12-01 2008-06-05 Organobalance Gmbh Compositions, kits and uses for protecting the skin against pathogenic microorganisms
KR100858840B1 (ko) * 2007-03-05 2008-09-17 (주)네오팜 신규 유산균 균주 및 이를 포함하는 유산균 제제
US20110002994A1 (en) * 2007-10-02 2011-01-06 Institut National De La Recherche Scientifique Method of regulating the th17 pathway and its associated metabolic impact
WO2012039615A2 (en) * 2010-09-21 2012-03-29 Winclove Bio Industries B.V. Commensal rat ileum bacterium (crib)
EA028340B1 (ru) 2011-06-08 2017-11-30 Новозимс А/С Лечение и профилактика инфекций, вызываемых helicobacter pylori у людей и животных, с помощью композиции, содержащей высушенные распылением клетки лактобактерий
US8906668B2 (en) * 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
CN105517557B (zh) * 2013-04-23 2021-11-30 特雷根控股有限公司 具有抗微生物活性的细菌菌株以及包含所述菌株的生物控制组合物
AR101538A1 (es) * 2014-09-25 2016-12-28 Terragen Holdings Ltd Cepas bacterianas que tienen actividad antimicrobiana y composiciones de biocontrol que las comprenden

Also Published As

Publication number Publication date
AU2018251616A1 (en) 2019-10-17
JP7494110B2 (ja) 2024-06-03
US20200376047A1 (en) 2020-12-03
CA3059453A1 (en) 2018-10-18
JP2020516684A (ja) 2020-06-11
EP3609515A4 (de) 2020-11-04
WO2018187838A1 (en) 2018-10-18
EP3609515A1 (de) 2020-02-19
CN110753553A (zh) 2020-02-04

Similar Documents

Publication Publication Date Title
SG11201908857QA (en) Methods for the treatment of inflammation and inflammatory conditions
SG11201901210UA (en) Ferroelectric memory cells
SG11201907857RA (en) Edible and biodegradable utensils
SG11201811048UA (en) Single-cell transcript sequencing
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201904535VA (en) Prevention and treatment of bone and cartilage damage or disease
SG11201810571RA (en) Compositions comprising bacterial strains
SG11201810443SA (en) Invasive medical devices including magnetic region and systems and methods
SG11201908971RA (en) Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
SG11201909963YA (en) Methods for treating dravet syndrome
SG11201901996UA (en) Formulations of ( r)-2-amino-3-phenylpropyl carbamate
SG11201809341PA (en) Mobile robot
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201808710UA (en) Novel immunogenic cd1d binding peptides
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201906748PA (en) Microbial cells, methods of producing the same, and uses thereof
SG11201908275XA (en) Peptides and methods for the treatment of diabetes
SG11201903076QA (en) Carbamoyl phenylalaninol compounds and uses therof
SG11201909602TA (en) Compositions and methods involving probiotic molecules
SG11201900486WA (en) Treatment and prevention of sleep disorders
SG11201906222WA (en) Jak1 selective inhibitors
SG11201808525UA (en) Anti-complement factor bb antibodies and uses thereof
SG11201806512VA (en) Copanlisib biomarkers
SG11201810192TA (en) Antibacterial compositions
SG11201807062RA (en) Anti-tnfalpha-antibodies and functional fragments thereof